{"id":100889,"date":"2025-08-22T06:44:10","date_gmt":"2025-08-22T06:44:10","guid":{"rendered":"https:\/\/www.mymsd.ch\/fr\/?post_type=product&p=100889"},"modified":"2025-08-22T06:44:27","modified_gmt":"2025-08-22T06:44:27","slug":"efficacite","status":"publish","type":"product","link":"https:\/\/www.mymsd.ch\/fr\/products\/welireg\/ls005\/efficacite\/","title":{"rendered":"Efficacit\u00e9"},"content":{"rendered":"\n

L’efficacit\u00e9 et la s\u00e9curit\u00e9 de WELIREG\u00ae ont \u00e9t\u00e9 \u00e9valu\u00e9es dans l’\u00e9tude de phase III LITESPARK-005<\/strong> par rapport \u00e0 l’\u00e9v\u00e9rolimus.1,2<\/sup><\/p>\n\n\n

\n
\n \n
\n \n
\n \n\n\n \n \n \n Plan de l\u2019\u00e9tude <\/span>\n \n \n\n \n \n <\/use>\n<\/svg>\n <\/span>\n <\/button>\n <\/h4>\n \n
\n \n\n
<\/div>\n\n\n\n

Plan de l\u2019\u00e9tude LITESPARK-0052<\/sup><\/strong><\/h4>\n\n\n
\n \"\"\n\n <\/figure>\n\n\n\n

L\u2019\u00e9tude clinique LITESPARK-005 a inclus des patient:es ayant re\u00e7u du belzutifan \u00e0 partir de la deuxi\u00e8me ligne (2L+) de traitement. Veuillez noter qu\u2019en Suisse, le belzutifan n\u2019est actuellement autoris\u00e9 pour le traitement du carcinome \u00e0 cellules r\u00e9nales avanc\u00e9 que pour les patient:es \u00e0 partir de la troisi\u00e8me ligne (3L+) de traitement.1<\/sup><\/p>\n\n\n\n

Illustration adapt\u00e9e d\u2019apr\u00e8s Rini B, et al. ESMO 2024.2<\/sup>
a. \u00c9valu\u00e9 par BICR selon RECIST-v1.1.<\/em><\/p>\n\n\n\n

<\/div>\n\n\n\n
Caract\u00e9ristiques des patient(e)s2<\/sup><\/strong><\/h5>\n\n\n
\n \"\"\n\n <\/figure>\n\n\n\n

L\u2019\u00e9tude clinique LITESPARK-005 a inclus des patient:es ayant re\u00e7u du belzutifan \u00e0 partir de la deuxi\u00e8me ligne (2L+) de traitement. Veuillez noter qu\u2019en Suisse, le belzutifan n\u2019est actuellement autoris\u00e9 pour le traitement du carcinome \u00e0 cellules r\u00e9nales avanc\u00e9 que pour les patient:es \u00e0 partir de la troisi\u00e8me ligne (3L+) de traitement.1<\/sup><\/p>\n\n\n\n

Tableau adapt\u00e9 d\u2019apr\u00e8s Rini B, et al. ESMO 2024.2<\/sup><\/em>
a. Le score KPS \u00e9tait manquant chez 0.3 % des patient:es dans chaque groupe de traitement.<\/em>
b. 0.5 % des patient:es du groupe WELIREG\u00ae et 1.1 % du groupe \u00e9v\u00e9rolimus avaient d\u00e9j\u00e0 eu 4 traitements ant\u00e9rieurs (violation du protocole).<\/em><\/p>\n\n <\/div>\n <\/div>\n<\/section>\n\n<\/div>\n\n<\/div>\n\n\n

\n \n
\n \n\n\n \n \n \n Aper\u00e7u de l’efficacit\u00e9 <\/span>\n \n \n\n \n \n <\/use>\n<\/svg>\n <\/span>\n <\/button>\n <\/h4>\n \n
\n \n\n
<\/div>\n\n\n\n

Aper\u00e7u de l’efficacit\u00e9 de WELIREG\u00ae dans l’\u00e9tude LITESPARK-0051<\/sup><\/strong><\/h4>\n\n\n\n

Le tableau r\u00e9sume les r\u00e9sultats d’efficacit\u00e9 de la premi\u00e8re analyse interm\u00e9diaire pr\u00e9d\u00e9finie pour le CCR avanc\u00e9 dans l’\u00e9tude LITESPARK-005.1<\/sup><\/p>\n\n\n\n

Dans l\u2019analyse finale, apr\u00e8s une dur\u00e9e m\u00e9diane de suivi de 19.6 mois, l\u2019OS n\u2019a pas atteint une significativit\u00e9 statistique (HR = 0.92, IC \u00e0 95 %: 0.77 \u2013 1.10; maturit\u00e9 des donn\u00e9es OS 69 %).1<\/sup><\/p>\n\n\n\n

<\/div>\n\n\n
\n \"\"\n\n <\/figure>\n\n\n\n

L\u2019\u00e9tude clinique LITESPARK-005 a inclus des patient:es ayant re\u00e7u du belzutifan \u00e0 partir de la deuxi\u00e8me ligne (2L+) de traitement. Veuillez noter qu\u2019en Suisse, le belzutifan n\u2019est actuellement autoris\u00e9 pour le traitement du carcinome \u00e0 cellules r\u00e9nales avanc\u00e9 que pour les patient:es \u00e0 partir de la troisi\u00e8me ligne (3L+) de traitement.1<\/sup><\/p>\n\n\n\n

Tableau adapt\u00e9 d\u2019apr\u00e8s l\u2019information professionnelle de WELIREG\u00ae.1<\/sup><\/em>
* Sur la base du mod\u00e8le de r\u00e9gression stratifi\u00e9 de Cox.<\/em>
** Sur la base de la m\u00e9thode des valeurs limites du produit (Kaplan-Meier) pour les donn\u00e9es censur\u00e9es<\/em><\/p>\n\n <\/div>\n <\/div>\n<\/section>\n\n<\/div>\n\n<\/div>\n\n\n

\n \n
\n \n\n\n \n \n \n PFS <\/span>\n \n \n\n \n \n <\/use>\n<\/svg>\n <\/span>\n <\/button>\n <\/h4>\n \n
\n \n\n
<\/div>\n\n\n\n

PFS dans l’\u00e9tude LITESPARK-005 lors de la premi\u00e8re analyse interm\u00e9diaire avec un suivi m\u00e9dian de 18.4 mois3<\/sup><\/strong><\/h4>\n\n\n\n

Am\u00e9lioration significative de la PFS sous WELIREG\u00ae vs \u00e9v\u00e9rolimus (p bilat\u00e9ral = 0.002)3,*<\/sup><\/p>\n\n\n

\n \"\"\n\n <\/figure>\n\n\n\n

L\u2019\u00e9tude clinique LITESPARK-005 a inclus des patient:es ayant re\u00e7u du belzutifan \u00e0 partir de la deuxi\u00e8me ligne (2L+) de traitement. Veuillez noter qu\u2019en Suisse, le belzutifan n\u2019est actuellement autoris\u00e9 pour le traitement du carcinome \u00e0 cellules r\u00e9nales avanc\u00e9 que pour les patient:es \u00e0 partir de la troisi\u00e8me ligne (3L+) de traitement.1<\/sup><\/p>\n\n\n\n

Graphique adapt\u00e9 d\u2019apr\u00e8s Choueiri TK, et al. NEJM 2024.3<\/sup><\/em>
* \u00c9valu\u00e9 par le BICR selon RECIST v1.1.<\/em><\/p>\n\n <\/div>\n <\/div>\n<\/section>\n\n<\/div>\n\n<\/div>\n\n\n

\n \n
\n \n\n\n \n \n \n OS <\/span>\n \n \n\n \n \n <\/use>\n<\/svg>\n <\/span>\n <\/button>\n <\/h4>\n \n
\n \n\n
<\/div>\n\n\n\n

OS dans l\u2019\u00e9tude LITESPARK-005 lors de l\u2019analyse finale de l\u2019efficacit\u00e9, avec un suivi m\u00e9dian de 35.8 mois2<\/sup><\/strong><\/h4>\n\n\n\n

OS sous WELIREG\u00ae vs \u00e9v\u00e9rolimus2<\/sup><\/p>\n\n\n

\n \"\"\n\n <\/figure>\n\n\n\n

L\u2019\u00e9tude clinique LITESPARK-005 a inclus des patient:es ayant re\u00e7u du belzutifan \u00e0 partir de la deuxi\u00e8me ligne (2L+) de traitement. Veuillez noter qu\u2019en Suisse, le belzutifan n\u2019est actuellement autoris\u00e9 pour le traitement du carcinome \u00e0 cellules r\u00e9nales avanc\u00e9 que pour les patient:es \u00e0 partir de la troisi\u00e8me ligne (3L+) de traitement.1<\/sup><\/p>\n\n\n\n

Graphique adapt\u00e9 d\u2019apr\u00e8s Rini B, et al. ESMO 2024.2<\/sup><\/em>
Dur\u00e9e moyenne de suivi entre la randomisation et la date butoir (15 avril 2024): 35.8 mois.<\/em>
RESTRICTION<\/em><\/strong>: aucun test statistique n\u2019a \u00e9t\u00e9 effectu\u00e9 pour les analyses actualis\u00e9es de la PFS, de l\u2019ORR et de la DOR. Aucune conclusion ne peut \u00eatre tir\u00e9e.<\/em><\/p>\n\n <\/div>\n <\/div>\n<\/section>\n\n<\/div>\n\n<\/div>\n\n\n

\n \n
\n \n\n\n \n \n \n ORR <\/span>\n \n \n\n \n \n <\/use>\n<\/svg>\n <\/span>\n <\/button>\n <\/h4>\n \n
\n \n\n
<\/div>\n\n\n\n

ORR dans l’\u00e9tude LITESPARK-005 lors de la premi\u00e8re analyse interm\u00e9diaire: r\u00e9ponse sup\u00e9rieure sous WELIREG\u00ae vs \u00e9v\u00e9rolimus1,*<\/sup><\/strong><\/h4>\n\n\n\n

82 patient(e)s pr\u00e9sentant un ORR sous WELIREG\u00ae vs 13 patient(e)s sous \u00e9v\u00e9rolimus (p < 0.00001)1<\/sup><\/p>\n\n\n

\n \"\"\n\n <\/figure>\n\n\n\n

L\u2019\u00e9tude clinique LITESPARK-005 a inclus des patient:es ayant re\u00e7u du belzutifan \u00e0 partir de la deuxi\u00e8me ligne (2L+) de traitement. Veuillez noter qu\u2019en Suisse, le belzutifan n\u2019est actuellement autoris\u00e9 pour le traitement du carcinome \u00e0 cellules r\u00e9nales avanc\u00e9 que pour les patient:es \u00e0 partir de la troisi\u00e8me ligne (3L+) de traitement.1<\/sup><\/p>\n\n\n\n

Graphique adapt\u00e9 d\u2019apr\u00e8s l\u2019information professionnelle de WELIREG\u00ae.1<\/sup><\/em>
* \u00c9valu\u00e9 par BICR selon RECIST-v1.1.
a. L\u2019ORR \u00e9tait un crit\u00e8re d\u2019\u00e9valuation secondaire cl\u00e9.<\/em><\/p>\n\n <\/div>\n <\/div>\n<\/section>\n\n<\/div>\n\n<\/div>\n\n <\/div>\n\n <\/div>\n\n\n\n

<\/div>\n\n\n\n
\n\n\n
\n \n Des exemplaires des publications de l’\u00e9tude peuvent \u00eatre demand\u00e9s \u00e0 dpoc.switzerland@msd.com si n\u00e9cessaire.<\/span>\n <\/a><\/div>\n\n\n
\n
\n \n
\n \n\n
Abr\u00e9viations<\/strong><\/em><\/strong><\/em><\/strong><\/em>:<\/h6>\n\n\n\n

BICR<\/strong>: examen central ind\u00e9pendant en aveugle (Blinded independent central review); CCR<\/strong>: carcinome \u00e0 cellules r\u00e9nales (renal cell carcinoma); ccRCC<\/strong>: carcinome r\u00e9nal \u00e0 cellules claires (clear cell renal cell carcinoma); DOR<\/strong>: dur\u00e9e de la r\u00e9ponse (duration of response); HR<\/strong>: Hazard Ratio; IC<\/strong>: intervalle de confiance; IMDC<\/strong>: International Metastatic RCC Database Consortium; KPS<\/strong>: Karnofsky Performance Status; ORR<\/strong>: taux de r\u00e9ponse global (objective response rate); OS<\/strong>: survie globale (overall response); PD-1<\/strong>: prot\u00e9ine 1 de la mort cellulaire programm\u00e9e (programmed cell death protein 1); PD-L1<\/strong>: ligand 1 de mort cellulaire programm\u00e9e (Programmed death-ligand 1); PFS<\/strong>: survie sans progression (progression-free survival); RECIST v1.1<\/strong>: Response Evaluation Criteria in Solid Tumors version 1.1; TKI<\/strong>: inhibiteur de la tyrosine kinase (tyrosine kinase inhibitor); VEGF\/R<\/strong>: facteur\/r\u00e9cepteur du facteur de croissance de l’endoth\u00e9lium vasculaire (vascular endothelial growth factor\/receptor).<\/em><\/p>\n\n<\/div>\n\n <\/div>\n\n <\/div>\n\n\n

\n
\n \n
\n \n\n
R\u00e9f\u00e9rences<\/em><\/em>:<\/strong><\/h6>\n\n\n\n
    \n \n
  1. \n Information professionnelle de WELIREG\u00ae (belzutifan),\u00a0www.swissmedicinfo.ch<\/a><\/mark><\/mark>, derni\u00e8re consultation le 22.08.2025.<\/em> <\/li>\n\n\n
  2. \n Rini B, et al. Final Analysis of the Phase 3 LITESPARK-005 Study of Belzutifan versus Everolimus in participant with previously treated advanced clear cell renal cell carcinoma presented at ESMO 2024, Barcelona, 13.\u201317. September 2024.<\/em> <\/li>\n\n\n
  3. \n Choueiri TK, et al. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. N Engl J Med. 2024;391:710 \u2013 21.<\/em> <\/li>\n\n<\/ol>\n\n<\/div>\n\n <\/div>\n\n <\/div>\n\n\n\n

    \u25bc Ce m\u00e9dicament fait l’objet d’une surveillance suppl\u00e9mentaire. Pour plus d\u2019informations, se r\u00e9f\u00e9rer \u00e0 l\u2019information professionnelle de WELIREG\u00ae disponible sous www.swissmedicinfo.ch<\/a>.<\/mark><\/em>

    Avant la prescription, veuillez consulter l\u2019information professionnelle compl\u00e8te publi\u00e9e sur     www.swissmedicinfo.ch<\/a>.<\/mark><\/em><\/p>\n\n\n

    \n \n Information professionnelle de WELIREG\u00ae<\/span>\n <\/a><\/div>\n\n\n
    \n \n Information professionnelle abr\u00e9g\u00e9e de WELIREG\u00ae<\/span>\n <\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

    Avec WELIREG\u00ae, une efficacit\u00e9 plus \u00e9lev\u00e9e par rapport \u00e0 l\u2019Everolimus a \u00e9t\u00e9 observ\u00e9e chez certain(e)s patient(e)s atteint(e)s de CCR avanc\u00e9.<\/p>\n","protected":false},"author":202221,"featured_media":100909,"parent":100887,"menu_order":2,"template":"","meta":{"_mhh_sticky_footer_settings":{"entityId":0},"_mhh_sticky_footer_posts":"","_mhh_sticky_footer_expanded":false,"_mhh_mcn_text_direction":"","_mhh_mcn_language":"","_mhh_mcn_left_sidebar_settings":{"entityId":0},"_mhh_mcn_sidebar_settings":{"entityId":0},"mhh_mcn_side_navigation_style":{"fontSize":{"l":"","m":"","s":""},"lineHeight":{"l":1.5,"m":1.5,"s":1.5},"itemColor":"","hoverItemColor":"","currentItemColor":"","borderItemColor":"","backgroundItemHoverColor":"","themeColor":""},"_mhh_mcn_child_page_navigation":{"isActive":true,"isSticky":true},"hide_header":false,"show_top_bar":false,"hide_footer":false,"full_width_layout":false,"product_resource":[],"related_products":"","fact_sheet":null,"scientific_title":"","job_code":"","banner":100910,"primary_logo":null,"secondary_logo":null,"icon":null,"primary_tag":1524,"editor_notices":[],"mconnectHideShareThis":false,"footnotes":"","mconnectIsArchiveTemplate":false,"mconnectArchiveFiltersDisabled":false,"mconnectArchiveLockAllPresetFilters":false,"mconnectArchiveHidePageSubmenu":false,"mconnectArchiveShowParentPageOnly":false,"mconnectArchiveDefaultOrder":"DESC","mconnectArchiveDefaultOrderBy":"date","mconnectArchivePostsPerPage":12,"mconnectArchivePostTypes":[],"mconnectArchiveAllowFilterBy":["category","tx-content-type","tx-product","tx-pathology","tx-active-ingredient","tx-therapeutic-area"],"mconnectArchiveTaxonomyOrder":[],"mconnectArchiveFilterSorting":["active","is_keyword","is_date"],"mconnectArchiveContentItemStyle":{"showExcerpt":true,"showImage":true,"showIcon":false,"showPrimaryTag":true,"showBorder":false,"showDates":false,"showCta":true,"isCard":false,"hasBackground":false,"showMetadata":true},"mconnectArchiveLayout":{"type":"list","hasFeatured":false},"mconnectDynamicTaxonomyEntities":[],"mconnectArchiveTerms_category":[],"mconnectArchiveAllowTerms_category":[],"mconnectArchiveTerms_tx-content-type":[],"mconnectArchiveAllowTerms_tx-content-type":[],"mconnectArchiveTerms_tx-product":[],"mconnectArchiveAllowTerms_tx-product":[],"mconnectArchiveTerms_tx-pathology":[],"mconnectArchiveAllowTerms_tx-pathology":[],"mconnectArchiveTerms_tx-active-ingredient":[],"mconnectArchiveAllowTerms_tx-active-ingredient":[],"mconnectArchiveTerms_tx-therapeutic-area":[],"mconnectArchiveAllowTerms_tx-therapeutic-area":[],"mconnectArchiveAllowTerms_dynamic-taxonomy":[],"mconnectArchiveLegacyDefaultTermsApplied":false,"mconnectContentUpdatesPerPage":10,"mconnectContentUpdatesViewMoreUrl":"","mconnectContentUpdatesTerms_tx-content-type":[],"mconnectContentUpdatesTerms_tx-product":[],"mconnectContentUpdatesTerms_tx-pathology":[],"mconnectContentUpdatesTerms_tx-active-ingredient":[],"mconnectContentUpdatesTerms_tx-therapeutic-area":[],"sidebar_toogle":0,"sidebar_toogle_notification_warning":true,"sidebar_toogle_notification_alert":true,"content_expiration_sidebar_date":"","content_expiration_sidebar_expired_post_status":"","content_expiration_sidebar_redirection":""},"categories":[693,791],"tags":[1524,1523],"ga4_page_audience":[],"ga4_page_birn_id":[],"ga4_page_branding":[957],"ga4_page_businessunit":[963],"ga4_page_campaign":[],"ga4_page_content_purpose":[],"ga4_page_customer_journey_stage":[],"ga4_page_customer_specialty":[],"ga4_page_experience":[],"ga4_page_indication":[],"ga4_page_material_intent":[1206],"ga4_page_product":[],"ga4_page_region":[],"ga4_page_therapeuticarea":[],"tx-therapeutic-area":[627,931],"tx-product":[1522],"tx-pathology":[930],"tx-content-type":[686],"tx-active-ingredient":[],"access":[],"user_status":[],"user_role":[],"class_list":["post-100889","product","type-product","status-publish","has-post-thumbnail","hentry","category-indications","category-oncology","tag-welireg-2","tag-welireg"],"yoast_head":"\nEfficacit\u00e9 - MyMSD.ch FR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.mymsd.ch\/fr\/products\/welireg\/ls005\/efficacite\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Efficacit\u00e9 - MyMSD.ch FR\" \/>\n<meta property=\"og:description\" content=\"Avec WELIREG\u00ae, une efficacit\u00e9 plus \u00e9lev\u00e9e par rapport \u00e0 l\u2019Everolimus a \u00e9t\u00e9 observ\u00e9e chez certain(e)s patient(e)s atteint(e)s de CCR avanc\u00e9.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.mymsd.ch\/fr\/products\/welireg\/ls005\/efficacite\/\" \/>\n<meta property=\"og:site_name\" content=\"MyMSD.ch FR\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-22T06:44:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/08\/F-WELIREG-aRCC-Thumbnail-Efficacy.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"611\" \/>\n\t<meta property=\"og:image:height\" content=\"430\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"16 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/products\/welireg\/ls005\/efficacite\/\",\"url\":\"https:\/\/www.mymsd.ch\/fr\/products\/welireg\/ls005\/efficacite\/\",\"name\":\"Efficacit\u00e9 - MyMSD.ch FR\",\"isPartOf\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/products\/welireg\/ls005\/efficacite\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/products\/welireg\/ls005\/efficacite\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/08\/F-WELIREG-aRCC-Thumbnail-Efficacy.jpg\",\"datePublished\":\"2025-08-22T06:44:10+00:00\",\"dateModified\":\"2025-08-22T06:44:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/products\/welireg\/ls005\/efficacite\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.mymsd.ch\/fr\/products\/welireg\/ls005\/efficacite\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/products\/welireg\/ls005\/efficacite\/#primaryimage\",\"url\":\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/08\/F-WELIREG-aRCC-Thumbnail-Efficacy.jpg\",\"contentUrl\":\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/08\/F-WELIREG-aRCC-Thumbnail-Efficacy.jpg\",\"width\":611,\"height\":430},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/products\/welireg\/ls005\/efficacite\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.mymsd.ch\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Products\",\"item\":\"https:\/\/www.mymsd.ch\/fr\/products\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"WELIREG\u00ae\",\"item\":\"https:\/\/www.mymsd.ch\/fr\/products\/welireg\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"WELIREG\u00ae pour l\u2019aRCC\",\"item\":\"https:\/\/www.mymsd.ch\/fr\/products\/welireg\/ls005\/\"},{\"@type\":\"ListItem\",\"position\":5,\"name\":\"Efficacit\u00e9\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#website\",\"url\":\"https:\/\/www.mymsd.ch\/fr\/\",\"name\":\"MyMSD.ch FR\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.mymsd.ch\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#organization\",\"name\":\"MSD Switzerland\",\"url\":\"https:\/\/www.mymsd.ch\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2023\/10\/cropped-myMSD-logo.png\",\"contentUrl\":\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2023\/10\/cropped-myMSD-logo.png\",\"width\":4084,\"height\":692,\"caption\":\"MSD Switzerland\"},\"image\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Efficacit\u00e9 - MyMSD.ch FR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.mymsd.ch\/fr\/products\/welireg\/ls005\/efficacite\/","og_locale":"fr_FR","og_type":"article","og_title":"Efficacit\u00e9 - MyMSD.ch FR","og_description":"Avec WELIREG\u00ae, une efficacit\u00e9 plus \u00e9lev\u00e9e par rapport \u00e0 l\u2019Everolimus a \u00e9t\u00e9 observ\u00e9e chez certain(e)s patient(e)s atteint(e)s de CCR avanc\u00e9.","og_url":"https:\/\/www.mymsd.ch\/fr\/products\/welireg\/ls005\/efficacite\/","og_site_name":"MyMSD.ch FR","article_modified_time":"2025-08-22T06:44:27+00:00","og_image":[{"width":611,"height":430,"url":"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/08\/F-WELIREG-aRCC-Thumbnail-Efficacy.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"16 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.mymsd.ch\/fr\/products\/welireg\/ls005\/efficacite\/","url":"https:\/\/www.mymsd.ch\/fr\/products\/welireg\/ls005\/efficacite\/","name":"Efficacit\u00e9 - MyMSD.ch FR","isPartOf":{"@id":"https:\/\/www.mymsd.ch\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.mymsd.ch\/fr\/products\/welireg\/ls005\/efficacite\/#primaryimage"},"image":{"@id":"https:\/\/www.mymsd.ch\/fr\/products\/welireg\/ls005\/efficacite\/#primaryimage"},"thumbnailUrl":"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/08\/F-WELIREG-aRCC-Thumbnail-Efficacy.jpg","datePublished":"2025-08-22T06:44:10+00:00","dateModified":"2025-08-22T06:44:27+00:00","breadcrumb":{"@id":"https:\/\/www.mymsd.ch\/fr\/products\/welireg\/ls005\/efficacite\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.mymsd.ch\/fr\/products\/welireg\/ls005\/efficacite\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.mymsd.ch\/fr\/products\/welireg\/ls005\/efficacite\/#primaryimage","url":"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/08\/F-WELIREG-aRCC-Thumbnail-Efficacy.jpg","contentUrl":"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2025\/08\/F-WELIREG-aRCC-Thumbnail-Efficacy.jpg","width":611,"height":430},{"@type":"BreadcrumbList","@id":"https:\/\/www.mymsd.ch\/fr\/products\/welireg\/ls005\/efficacite\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.mymsd.ch\/fr\/"},{"@type":"ListItem","position":2,"name":"Products","item":"https:\/\/www.mymsd.ch\/fr\/products\/"},{"@type":"ListItem","position":3,"name":"WELIREG\u00ae","item":"https:\/\/www.mymsd.ch\/fr\/products\/welireg\/"},{"@type":"ListItem","position":4,"name":"WELIREG\u00ae pour l\u2019aRCC","item":"https:\/\/www.mymsd.ch\/fr\/products\/welireg\/ls005\/"},{"@type":"ListItem","position":5,"name":"Efficacit\u00e9"}]},{"@type":"WebSite","@id":"https:\/\/www.mymsd.ch\/fr\/#website","url":"https:\/\/www.mymsd.ch\/fr\/","name":"MyMSD.ch FR","description":"","publisher":{"@id":"https:\/\/www.mymsd.ch\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.mymsd.ch\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.mymsd.ch\/fr\/#organization","name":"MSD Switzerland","url":"https:\/\/www.mymsd.ch\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.mymsd.ch\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2023\/10\/cropped-myMSD-logo.png","contentUrl":"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2023\/10\/cropped-myMSD-logo.png","width":4084,"height":692,"caption":"MSD Switzerland"},"image":{"@id":"https:\/\/www.mymsd.ch\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/product\/100889","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/types\/product"}],"author":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/users\/202221"}],"version-history":[{"count":13,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/product\/100889\/revisions"}],"predecessor-version":[{"id":100928,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/product\/100889\/revisions\/100928"}],"up":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/product\/100887"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/media\/100909"}],"wp:attachment":[{"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/media?parent=100889"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/categories?post=100889"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tags?post=100889"},{"taxonomy":"ga4_page_audience","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_audience?post=100889"},{"taxonomy":"ga4_page_birn_id","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_birn_id?post=100889"},{"taxonomy":"ga4_page_branding","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_branding?post=100889"},{"taxonomy":"ga4_page_businessunit","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_businessunit?post=100889"},{"taxonomy":"ga4_page_campaign","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_campaign?post=100889"},{"taxonomy":"ga4_page_content_purpose","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_content_purpose?post=100889"},{"taxonomy":"ga4_page_customer_journey_stage","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_customer_journey_stage?post=100889"},{"taxonomy":"ga4_page_customer_specialty","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_customer_specialty?post=100889"},{"taxonomy":"ga4_page_experience","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_experience?post=100889"},{"taxonomy":"ga4_page_indication","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_indication?post=100889"},{"taxonomy":"ga4_page_material_intent","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_material_intent?post=100889"},{"taxonomy":"ga4_page_product","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_product?post=100889"},{"taxonomy":"ga4_page_region","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_region?post=100889"},{"taxonomy":"ga4_page_therapeuticarea","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_therapeuticarea?post=100889"},{"taxonomy":"tx-therapeutic-area","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tx-therapeutic-area?post=100889"},{"taxonomy":"tx-product","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tx-product?post=100889"},{"taxonomy":"tx-pathology","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tx-pathology?post=100889"},{"taxonomy":"tx-content-type","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tx-content-type?post=100889"},{"taxonomy":"tx-active-ingredient","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tx-active-ingredient?post=100889"},{"taxonomy":"access","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/access?post=100889"},{"taxonomy":"user_status","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/user_status?post=100889"},{"taxonomy":"user_role","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/user_role?post=100889"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}